Component Synergy Research Research into BPC-157 and TB-500 individually demonstrates their complementary mechanisms - BPC-157's vascular and protective effects pair with TB-500's cellular migration capabilities
How do oral and injectable BPC 157 compare
In a phase 3 clinical trial, this AAV9 vector has found success in intravenously delivering the SMA1 transgeneeffectively restoring motor functions in SMA patients [157, 158]
In other embodiments, a therapeutically effective amount of at least one otic agent is released from the formulation or composition for a time period exceeding 5 minutes, or 15 minutes, or 30 minutes, or 1 hour, or 4 hours, or 6 hours, or 12 hours, or 18 hours, or 1 day, or 2 days, or 3 days, or 4 days, or 5 days, or 6 days, or 7 days, or 10 days, or 12 days, or 14 days, or 18 days, or 21 days, or 25 days, or 30 days, or 45 days, or 2 months, or 3 months, or 4 months, or 5 months, or 6 months, or 9 months, or 1 year
The large intestine and upper gastrointestinal tract are rarely affected
